Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer.

Cancer - 1 Sept 2015

Ni Jun, Liu Dong-Yang, Hu Bei, Li Chen, Jiang Ji, Wang Han-Ping, Zhang Li

Abstract excerpt

BACKGROUND: The current study was conducted to explore the relationship between icotinib hydrochloride exposure and therapeutic effects in Chinese patients with advanced non-small cell lung cancer (NSCLC) who were treated with icotinib hydrochloride. METHODS: A total of 30 patients with NSCLC who were treated with icotinib hydrochloride were chosen from a single-center, open-label, phase 1 dose escalation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to China

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crown Ethers

Share to Disease-Free Survival

Share to ErbB Receptors

Share to Kaplan-Meier Estimate

Share to Neoplasm Staging

Share to Quinazolines

Source

Identifiers

PMID: 26331821
DOI: 10.1002/cncr.29568

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer.PMID 26331821Read ↗

Efficacy and influence factors of icotinib hydrochloride in treating advanced non-small cell lung cancer.Semantic proximity Read ↗

[Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].Semantic proximity Read ↗

A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

[Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].Semantic proximity Read ↗

Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.Semantic proximity Read ↗

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.Semantic proximity Read ↗

Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.Semantic proximity Read ↗

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials.Semantic proximity Read ↗

A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

[The therapeutic value and safety of icotinib as first-line therapy for advanced non-small cell lung cancer patients].Semantic proximity Read ↗

[Clinical Analysis of Icotinib on Beneficiary of Advanced Non-small Cell Lung Cancer with EGFR Common Mutation].Semantic proximity Read ↗

[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.